Canaccord cuts Stryker stock price target on manufacturing woes

Canaccord Genuity cut Stryker's price target to $385 from $400 while retaining a Buy rating, citing persistent manufacturing constraints in Peripheral Vascular and weaker-than-expected Joint Replacement seasonality. The supply issue, initially expected to resolve in Q3, is now expected to affect Q4; SYK trades at $280.24, about 5% above its 52-week low and down nearly 20% year to date. The headwinds offset a Q2 2026 earnings beat of $3.69 per share versus $3.49 consensus on $6.6B of revenue, while Stryker raised the low end of its fiscal-2026 organic-growth and EPS guidance.

Analysis

The investable issue is not the near-term revenue miss but the duration of lost procedure-level share. Peripheral Vascular shortages create an opening for Boston Scientific (BSX), Abbott (ABT) and Medtronic (MDT) to convert new-account opportunities into recurring physician preference; in medtech, restored supply does not automatically restore utilization once cath-lab protocols and sales coverage shift. A fourth-quarter resolution would therefore limit the direct revenue drag but may not prevent a 6-18 month share-recapture cost through pricing, inventory support and elevated commercial spending.

SYK's valuation discount should be assessed against whether the problem is isolated manufacturing execution or evidence of broader quality-system fragility following multiple operational disruptions. The market will likely tolerate a modest 2026 guide reset if management provides verified output recovery, backlog conversion and stable gross margin; it will not tolerate another timing slip, because that converts a temporary supply constraint into a credibility and multiple-compression event. Joint-replacement softness is also more consequential than seasonality if it reflects elective-procedure mix pressure or share loss to Zimmer Biomet (ZBH) and Johnson & Johnson (JNJ).

Near term, the sell-side estimate-reset cycle can remain a headwind into the next earnings print, but the low starting price embeds meaningful skepticism relative to the stated long-term growth framework. Consensus may be over-weighting the supply disruption while under-weighting capital backlog and Trauma & Extremities resilience; however, that is only a buyable contrarian setup after evidence that constrained orders are shipping rather than merely accumulating. The cleanest relative expression is SYK versus ZBH: SYK has higher execution risk, while ZBH offers more direct upside if joint-replacement demand normalizes without a comparable supply issue.

Key Decisions for Investors

• Maintain a tactical underweight in SYK for the next 1-3 months; do not add solely on analyst target-price support. Cover the underweight if management quantifies Peripheral Vascular output normalization before the next results and maintains full-year organic-growth and EPS ranges.
• Pair trade: long ZBH / short SYK, sized market-neutral, through the next earnings cycle. Target 8-12% relative upside if hip demand and supply constraints persist; stop if SYK demonstrates sequential Peripheral Vascular shipment recovery and ZBH reports weaker-than-expected knees/hips procedure growth.
• Monitor BSX and ABT for acceleration in vascular growth or commentary on new-account wins; a confirmed share-transfer signal supports adding to BSX versus SYK over 6-12 months, while absence of that signal argues the disruption is transitory rather than structural.
• Revisit a long SYK only after two data points: backlog declines sequentially because shipments improve, and gross margin does not deteriorate from remediation or expedited freight. If either fails, downside is more likely driven by 2027 estimate cuts than the current-year revenue shortfall.